Table 1: Patient's clinicopathological features (N = 245).
|
Clinicopathological variables |
Number of patients, n (%) |
|
|
Family history (breast or ovarian cancer) |
Positive |
13 (5.3) |
|
Negative |
112 (45.7) |
|
|
Unknown |
120 (49.0) |
|
|
Menopausalstatus |
Premenopausal |
140 (57.1) |
|
Postmenopausal |
104 (42.4) |
|
|
Unknown |
1 (4) |
|
|
HER2 |
Positive |
32 (13.1) |
|
Negative |
140 (57.1) |
|
|
Unknown |
73 (29.8) |
|
|
HER2status |
Negative |
140 (57.1) |
|
Positive |
32 (13.1) |
|
|
Need FISH/CISH |
14 (5.7) |
|
|
Unknown |
59 (24.1) |
|
|
Histopathology type |
IDC |
202 (82.4) |
|
Lobular |
24 (9.8) |
|
|
Other types |
19 (7.8) |
|
|
Histopathology grade |
1 |
9 (3.7) |
|
2 |
119 (48.6) |
|
|
3 |
99 (40.4) |
|
|
Unknown |
18 (7.3) |
|
|
Clinical stage |
Stage 1 |
13 (5.3) |
|
Stage 2 |
114 (46.5) |
|
|
Stage 3 |
86 (35.1) |
|
|
Stage 4 |
30 (12.2) |
|
|
Unknown |
2 (0.8) |
|
|
Tumor stage |
T1 |
24 (9.8) |
|
T2 |
141 (57.6) |
|
|
T3 |
47 (19.2) |
|
|
T4 |
23 (9.4) |
|
|
Unknown |
10 (4.1) |
|
|
Nodal stage |
N0 |
75 (30.6) |
|
N1 |
93 (38.0) |
|
|
N2 |
56 (22.9) |
|
|
N3 |
11 (4.5) |
|
|
Unknown |
10 (4.1) |
|
|
Lymphnodestatus |
Positive |
160 (65.3) |
|
Negative |
75 (30.6) |
|
|
Unknown |
10 (4.1) |
|
|
NumberLNs |
0 |
75 (30.6) |
|
1-3 |
60 (24.5) |
|
|
4-9 |
55 (22.4) |
|
|
> 9 |
37 (15.1) |
|
|
Unknown |
18 (7.3) |
|
|
Metastases at diagnosis |
M0 |
212 (86.5) |
|
M1 |
30 (12.2) |
|
|
Unknown |
3 (1.2) |
|
|
Recurrence at follow-up (local or distant) |
Yes |
70 (28.6) |
|
No |
150 (61.2) |
|
|
Primary metastasis at diagnosis |
25 (10.2) |
|
|
Status at last follow-up |
Dead |
52 (21.2) |
|
Alive free of disease |
154 (62.9) |
|
|
Alive with disease |
39 (15.9) |
|